Ana C. De Jesus-Acosta

Ana C. De Jesus-Acosta

Oncology

201 North Broadway Street, Viragh BLDG 5th FL
Viragh BLDG 5th FL
Baltimore, MD 21287

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 53 publications

Assessment of colorectal cancer recurrence risk following solid organ transplantation.

Assessment of colorectal cancer recurrence risk following solid organ transplantation.

Journal: Journal of gastrointestinal oncology

Published: November 25, 2025

Correction: Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair-Proficient Colorectal Cancer.

Correction: Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair-Proficient Colorectal Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: October 27, 2025

Safety and immunologic impact of neoadjuvant/adjuvant GVAX, cyclophosphamide, pembrolizumab, and anti-CSF1R agent IMC-CS4 in pancreatic adenocarcinoma.

Safety and immunologic impact of neoadjuvant/adjuvant GVAX, cyclophosphamide, pembrolizumab, and anti-CSF1R agent IMC-CS4 in pancreatic adenocarcinoma.

Journal: Frontiers in immunology

Published: September 29, 2025

Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair-Proficient Colorectal Cancer.

Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair-Proficient Colorectal Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 03, 2025

A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borderline Resectable Pancreatic Adenocarcinoma.

A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borderline Resectable Pancreatic Adenocarcinoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: October 15, 2024

Genomic Landscape of Pancreatic Neuroendocrine Tumors and Implications for Clinical Practice.

Genomic Landscape of Pancreatic Neuroendocrine Tumors and Implications for Clinical Practice.

Journal: JCO precision oncology

Published: September 04, 2024

New onset diabetes predicts clinical outcomes in patients with pancreatic adenocarcinoma.

New onset diabetes predicts clinical outcomes in patients with pancreatic adenocarcinoma.

Journal: Journal of gastrointestinal oncology

Published: July 25, 2024

Clinical outcomes of liposomal irinotecan in patients with advanced pancreatic cancer previously treated with conventional irinotecan: A meta-analysis of real-world evidence.

Clinical outcomes of liposomal irinotecan in patients with advanced pancreatic cancer previously treated with conventional irinotecan: A meta-analysis of real-world evidence.

Journal: Cancer

Published: January 30, 2024

Elevated Baseline Mean Corpuscular Volume Predicts the Development of Severe Hematologic Toxicity After 177Lu-DOTATATE Therapy.

Elevated Baseline Mean Corpuscular Volume Predicts the Development of Severe Hematologic Toxicity After 177Lu-DOTATATE Therapy.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: January 17, 2024

Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors.

Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors.

Journal: Cancer prevention research (Philadelphia, Pa.)

Published: November 17, 2023

Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial.

Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial.

Journal: Nature cancer

Published: August 03, 2023

Clinical outcomes of liposomal irinotecan in advanced pancreatic adenocarcinoma patients previously treated with conventional irinotecan-based chemotherapy: a real-world study.

Clinical outcomes of liposomal irinotecan in advanced pancreatic adenocarcinoma patients previously treated with conventional irinotecan-based chemotherapy: a real-world study.

Journal: Frontiers in oncology

Published: June 29, 2023

Showing 1-12 of 53

Last Updated: 09/26/2026